Take­da kicks up GPCR work with So­sei Hep­tares, dish­ing out $26M to get GI drug dis­cov­ery go­ing

Take­da is join­ing the grow­ing group of big-league play­ers en­list­ing the GPCR ex­perts at So­sei Hep­tares for drug de­sign work.

Much like the Genen­tech deal un­veiled days ago, the part­ner­ship with Take­da comes with $26 mil­lion in up­front and near-term mile­stones, with mile­stones adding up to $1.2 bil­lion. So­sei Hep­tares will ap­ply its tech­nol­o­gy — which gen­er­ates both small mol­e­cules and an­ti­bod­ies based on sta­bi­lized GPCR struc­tures — on a range of dis­eases, fo­cus­ing ini­tial­ly on gut in­flam­ma­tion and motil­i­ty dis­or­ders.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.